Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.

Brown, A

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. [electronic resource] - Journal of viral hepatitis 05 2018 - 457-464 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1365-2893

10.1111/jvh.12801 doi


Adolescent
Adult
Aged
Aged, 80 and over
Amides
Antiviral Agents--administration & dosage
Benzofurans--administration & dosage
Carbamates
Cyclopropanes
Drug Therapy, Combination--adverse effects
Drug-Related Side Effects and Adverse Reactions--epidemiology
Female
Genotype
Hepacivirus--classification
Hepatitis C, Chronic--drug therapy
Humans
Imidazoles--administration & dosage
Male
Middle Aged
Quinoxalines--administration & dosage
Ribavirin--administration & dosage
Sulfonamides
Sustained Virologic Response
Treatment Outcome
Young Adult